Ignite Creation Date:
2024-05-05 @ 7:49 PM
Last Modification Date:
2024-10-26 @ 9:54 AM
Study NCT ID:
NCT00748410
Status:
TERMINATED
Last Update Posted:
2020-10-30
First Post:
2008-09-05
Brief Title:
Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative Colitis
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
An Open Label 7-day Repeat Dose Study to Evaluate the Pharmacodynamics of SB-656933-AAA in Patients With Ulcerative Colitis
Status:
TERMINATED
Status Verified Date:
2020-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
SB-656933 is no longer being developed for ulcerative colitis
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will involve the use of a new compound SB-656933 Accumulation of inflammatory white blood cells mostly polymorphonuclear neutrophilsin the gut colon may be contributing to the pathology of ulcerative colitis It has been shown that SB-656933 reduces polymorphonuclear neutrophils PMN accumulation in pre-clinical models of colitis 99m-Tc-HMPAO scintigraphy is a imaging technique which will be used in this study to observe the effect of SB656933 on the migration of PMN to inflamed tissue
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2007-005520-32 | EUDRACT_NUMBER | None | None |